New mRNA Cancer Vaccine Design Reduces Toxicity While Boosting Immune Response

Current mRNA cancer vaccines face a critical limitation: while they can expand tumor-specific T cells, these cells often lack the potent effector function needed to eliminate cancer effectively. Researchers at Tsinghua University have developed an innovative solution that could transform cancer vaccine design.

The team screened various cytokines as vaccine adjuvants and identified IL-12 as highly effective for enhancing T cell responses. However, systemic IL-12 causes severe toxicity, limiting its clinical use. To overcome this challenge, they engineered a membrane-tethered IL-12 (mtIL12) that remains anchored to the surface of antigen-presenting cells.

This clever design restricts IL-12 activity to the immediate vicinity of antigen presentation, selectively activating tumor-specific T cells without affecting bystander immune cells. The mtIL12 adjuvant mRNA vaccine induced a unique population of pre-effector T cells that rapidly differentiate into highly responsive effector cells upon tumor encounter.

In mouse cancer models, the mtIL12 vaccine demonstrated superior anti-tumor activity compared to conventional approaches. Remarkably, it overcame resistance to immune checkpoint therapy and effectively prevented cancer metastasis. The membrane-tethering strategy eliminated the systemic toxicity associated with free IL-12 while maintaining potent immune activation.

This breakthrough represents a significant advance in cancer vaccine technology, offering a path to more effective immunotherapy with improved safety profiles. The approach could potentially be applied to other cytokine adjuvants, opening new possibilities for precision cancer treatment.